Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Mesna→

Mesna Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
19767-45-4
Molecular formula
C2H5NaO3S2
Molecular weight
164.18 g/mol
Drug class
Uroprotective thiol compounddetoxifying agent for oxazaphosphorine-derived urotoxic metabolites
Mechanism of action
The sulfhydryl group of mesna reacts chemically with urotoxic ifosfamide metabolites, particularly acrolein, in urine to form stable, less toxic thioether products, reducing haemorrhagic cystitis risk. It does not prevent other systemic toxicities of ifosfamide.
Indications / reported uses
  • Prevention of ifosfamide-induced haemorrhagic cystitis in patients receiving ifosfamide; the administration schedule is tied to the ifosfamide regimen and product instructions

Sources: US DailyMed — Mesna injection/tablets · NLM MeSH — Mesna · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Mesna Environmental Risk Assessment (ERA) (the Mesna ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.